首页> 外文期刊>Respiration: International Review of Thoracic Diseases >Clinical Predictors of Successful and Earlier Removal of Indwelling Pleural Catheters in Benign Pleural Effusions
【24h】

Clinical Predictors of Successful and Earlier Removal of Indwelling Pleural Catheters in Benign Pleural Effusions

机译:成功和早期去除良性胸膜胸腔的胸腔导管的临床预测因子

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Indwelling pleural catheters (IPCs) are an emerging therapy for persistent benign pleural effusions. IPCs may achieve pleurodesis and be removed. Objectives: We aimed to identify factors associated with higher pleurodesis rates and earlier IPC removal in benign pleural effusions. Methods: We reviewed a database of IPCs inserted for nonmalignant pleural effusions in the period August 2007 to June 2017 in patients who underwent medical thoracoscopy (MT). Clinical, radiologic, and pleural fluid data were recorded. Logistic regression and Cox proportional hazards were used to assess the rate of and time to pleurodesis. Results: 304 IPCs were reviewed. 52 were excluded from the pleurodesis analysis due to removal for another reason, or because of an eventual diagnosis of malignant disease. The overall pleurodesis rate was 74%, and median time to pleurodesis was 42 (IQR 18-93) days. Variables with increased pleurodesis rates in multivariate analysis include Eastern Cooperative Oncology Group performance status score of <= 2 (odds ratio [OR] 4.22, 95% confidence interval [CI] 1.75-10.16) and MT (OR 5.27, 95% CI 2.74-10.11). No variables were associated with reduced pleurodesis rates in multivariate analysis. Variables that predicted earlier removal in multivariate analysis included secondary pleural infection (hazard ratio [HR] 14.19, 95% CI 4.11-48.91), % eosinophils (HR 1.03, 95% CI 1.01-1.05), and connective tissue disease (HR 2.59, 95% CI 1.20-5.57). Variables that predicted delayed removal include pleural effusion above the hilum (HR 0.54, 95% CI 0.34-0.85), liver failure (HR 0.31, 95% CI 0.16-0.60), and heart failure (HR 0.32, 95% CI 0.20-0.52). Conclusions: IPCs are safe in benign effusions. Clinicians should consider numerous factors when predicting the rate of and time to pleurodesis.
机译:背景:留置胸膜导管(IPC)是持续良性胸膜湿度的新兴疗法。 IPC可以实现胸膜瘤和移除。目的:我们旨在识别与良性胸腔有效性更高的血流瘤率和早期IPC去除相关的因素。方法:我们审查了2007年8月期间介绍了非对期胸膜潮流的IPCS数据库,从2007年8月至2017年6月接受了医疗胸腔镜检查(MT)的患者。记录临床,放射学和胸腔流体数据。 Logistic回归和Cox比例危害用于评估血液缺失的速率和时间。结果:审查了304个IPC。由于另外的原因除去,或由于对恶性疾病的最终诊断而被排除在肽分析之外。整体血液瘤率为74%,胸膜中的中值时间为42(IQR 18-93)天。多变量分析中具有较高的胸膜炎率的变量包括<= 2的东方合作肿瘤组性能状态得分(差距率[或] 4.22,95%置信区间[CI] 1.75-10.16)和MT(或5.27,95%CI 2.74- 10.11)。没有变量与多变量分析中的胸膜炎率降低相关。预测在多变量分析中提前去除的变量包括二次胸腔感染(危险比[HR] 14.19,95%CI 4.11-48.91),%嗜酸性粒细胞(HR 1.03,95%CI 1.01-1.05)和结缔组织疾病(HR 2.59, 95%CI 1.20-5.57)。预测延迟去除的变量包括高于Hilum以上的胸腔积液(HR 0.54,95%CI 0.34-0.85),肝功能衰竭(HR 0.31,95%CI 0.16-0.60)和心力衰竭(HR 0.32,95%CI 0.20-0.52 )。结论:IPCS在良性潮流中是安全的。临床医生在预测血液缺失的速率和时间时应考虑许多因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号